FRISQ and Dartmouth–Hitchcock Medical Center (DHMC) in New Hampshire, United States, have signed a letter of intent to enter into a licensing agreement under which FRISQ Care will initially be used in the treatment of heart failure. During the coming period, the plan is to configure FRISQ Care to enable DHMC and its regional care providers on the U.S. east coast to create a unique, interactive care plan for each patient that provides continuous communication and information exchange between health care personnel and the patient.
Patients being treated for heart failure are normally admitted to the hospital for recurring and prolonged periods. With DHMC’s new program, a greater degree of care will be provided in the patient’s immediate area or home, following initial diagnosis and determination of the patient’s individualized care plan.
“It is gratifying that an institution as highly esteemed as DHMC has selected FRISQ as a partner. We are looking forward to soon finalizing a licensing agreement, under which FRISQ Care will be utilized to reduce unnecessary hospital admissions and enable the provision of care on a more local basis via clinics, health centers and home care,” says Martin Irding, CEO of FRISQ.
Dartmouth–Hitchcock Medical Center is a leading care provider on the U.S. east coast, with over 12,000 employees and more than 1.9 million patients. DHMC and FRISQ expect the collaboration to result in more effective coordination, administrative savings, fewer hospital admissions, greater patient involvement and improved health outcomes.
With FRISQ Care, DHMC’s specialists can continuously monitor the patient’s health development and proactively intervene in the event health outcomes fail to follow the care plan. Another objective for using FRISQ Care is to increase patients’ awareness, motivation and involvement in their own treatment.
“2020 will be an exciting year for FRISQ in the U.S. There is a great deal of interest in FRISQ and the functionality we offer, both in the U.S. and in Europe. It is especially encouraging to have the opportunity to utilize FRISQ Care for heart failure, as this is one of the most widespread, costly health care processes. This complements the experience we have gained in Sweden in applying FRISQ Care to health care processes such as COPD, diabetes, mental illness, back surgery and cancer,” concludes Martin Irding.
This press release is a translation of the original Swedish text. In the event of inconsistency or discrepancy between the Swedish version and this publication, the Swedish language version shall prevail.
For further information:
Martin Irding, CEO FRISQ
+46 (0)8 120 131 21